China Biologic Products to Attend at Susquehanna's Third Annual Beijing Management Summit
September 10 2009 - 8:00AM
PR Newswire (US)
The Company will participate on China Pharma-Biotech Panel TAI'AN,
Shandong, China, Sept. 10 /PRNewswire-Asia-FirstCall/ -- China
Biologic Products, Inc. (OTC:CBPO) (BULLETIN BOARD: CBPO) ("China
Biologic," or the "Company"), one of the leading plasma-based
pharmaceutical companies in the People's Republic of China ("PRC"),
operating through its indirect majority-owned subsidiaries,
Shandong Taibang Biological Products Co. Ltd. ("Taibang") and
Chongqing Dalin Biologic Technologies Co., Ltd. ("Dalin") and its
equity investment in Xi'an Huitian Blood Products Co., Ltd.
("Huitian"), today announced that the Company's management team
will attend the upcoming Susquehanna International Group of
Companies ("SIG") 3rd Annual Beijing Management Summit, and the
Company's CEO, Mr. Colin Zhao, and newly appointed Director of
Research and Development, Dr. Vincent Xie, will participate on the
China Pharma-Biotech Panel at the conference. The 3rd Annual
Beijing Management Summit is a two-day conference that brings
together executives from public and private companies based in
China and other emerging Asian economies. The event will showcase
leading companies in the Chinese Consumer, Health Care, Internet,
and Technology sectors, as well as companies in the IT
Services/Outsourcing and Financial Technologies sectors. The event
format will consist of one-on-one meetings and company
presentations. The date and location of China Biologic's one-on-one
meetings and the China Pharma-Biotech Panel at the SIG 3rd Annual
Beijing Management Summit are as follows: Date: September 16 - 17,
2009 Location: The Grand Hyatt Beijing Hotel 1 East Chang An Avenue
Beijing 100738 Panel Schedule: China Pharma-Biotech Panel September
16, 2009 1:05-2:10 PM Beijing Time Drawing Room IV China Biologic
will be available for one-on-one meetings with analysts and
portfolio managers during the summit. Interested parties and
investors who wish to meet with China Biologic's management may
contact , phone +1-(646) 701-7445, or contact SIG institutional
sales directly. Participation in the SIG 3rd Annual Beijing
Management Summit is by invitation only. About China Biologic
Products, Inc. China Biologic Products, Inc. (the "Company"),
through its indirect majority-owned subsidiaries, Shandong Taibang
Biological Products Co. Ltd. and Chongqing Dalin Biologic
Technologies Co., Ltd, and its equity investment in Xi'an Huitian
Blood Products Co., Ltd., is currently the largest non-state-owned
plasma-based biopharmaceutical company in China. The Company is a
fully integrated biologic products company with plasma collection,
production and manufacturing, research and development, and
commercial operations. The Company's plasma-based biopharmaceutical
products are irreplaceable during medical emergencies, and are used
for the prevention and treatment of various diseases. It sells its
products to hospitals and other healthcare facilities in China. For
more information, please contact: Company Contact: Mr. Y. Tristan
Kuo Chief Financial Officer China Biologic Products, Inc. Tel:
+86-538-6202206 Email: Web: http://www.chinabiologic.com/ Investor
Relations Contact: Mr. Crocker Coulson, President CCG Investor
Relations Tel: +1-646-213-1915 (NY office) or Mr. Gary Chin Tel:
+1-646-213-1909 Email: Web: http://www.ccgirasia.com/ DATASOURCE:
China Biologic Products, Inc. CONTACT: Y. Tristan Kuo, Chief
Financial Officer of China Biologic Products, Inc.,
+86-538-6202206, ; or Investors, Crocker Coulson, President,
+1-646-213-1915, , or Gary Chin, +1-646-213-1909, both of CCG
Investor Relations Web site: http://www.chinabiologic.com/
http://www.ccgirasia.com/
Copyright